An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

Table 1 Representative IPA categories associated with glutamate andcandesartan-glutamate comparison

Categories	Diseases or functions annotation	p value	No. of molecules
Cellular movement	Cell movement	8.33E-52	170
Cell-to-cell signaling and interaction, cellular movement	Recruitment of cells	1.61E-49	72
Hematological system development and function, tissue morphology	Quantity of blood cells	4.80E-46	114
Inflammatory response	Inflammation of organ	1.61E-45	119
Organismal injury and abnormalities	Lesion formation	1.67E-44	73
Cardiovascular disease	Vascular disease	1.33E-42	105
Immunological disease	Systemic autoimmune syndrome	7.31E-41	108
Endocrine system disorders, gastrointestinal disease, metabolic disease	Diabetes mellitus	1.60E-36	102
Cell death and survival	Cell death	2.16E-35	191
Metabolic disease	Glucose metabolism disorder	1.13E-33	109
Inflammatory disease	Chronic inflammatory disorder	1.54E-33	94
Cardiovascular system development and function, organismal development	Development of blood vessel	1.07E-27	83
Free radical scavenging	Synthesis of reactive oxygen species	5.38E-27	59

The number of molecules represents the number of genes differentially expressed between glutamate and candesartan + glutamate that are part of the pathway category. The whole ingenuity pathway analysis (IPA) output is provided as Additional file 3: Table S3

ISSN: 1758-9193